Figure 2
The group of relatively longer living patients displays a stronger HPV16-specific immune response upon vaccination. The patients are grouped according to the median survival time (12.6 months) of the whole group. The strength (median + interquartile range) of the indicated immune response to all 6 pools of HPV16 E6 and E7 peptides for the group of patients with survival time equal or less than 12.6 months versus that of the group of patients with a survival time beyond 12.6 months measured before vaccination (pre-vac), after 2 vaccinations (2-vac) and after the 3rd or 4th vaccination (3/4-vac) is given. Only when the strength of the immune response was significantly different, this is indicated by the p-value.